Association of large intergenic noncoding RNA expression with disease activity and organ damage in systemic lupus erythematosus

Table 1 Large intergenic noncoding RNA linc0949 by presence or absence of clinical features of systemic lupus erythematosus ^a

Clinical features		SLE clinical features present		SLE clinical features absent		P -value
		N	Mean ± SEM (range, 10 ⁻³ )	N	Mean ± SEM (range, 10 ⁻³ )	P -value
Renal		50	2.16 ± 0.152	52	1.47 ± 0.132	0.0014
Rash		33	1.89 ± 0.200	69	1.87 ± 0.199	NS
Arthritis		35	1.79 ± 0.327	67	1.97 ± 0.163	NS
Serositis		21	1.81 ± 0.307	81	1.72 ± 0.364	NS
Mucosal ulcer		19	2.02 ± 0.207	83	1.87 ± 0.187	NS
Hematologic		30	1.84 ± 0.243	72	2.06 ± 0.179	NS
Neurologic		9	1.99 ± 0.084	93	2.05 ± 0.45	NS
Autoantibodies
	Anti-dsDNA	40	1.91 ± 0.274	62	1.88 ± 0.264	NS
	Anti-Sm	16	2.07 ± 0.202	86	1.78 ± 0.193	NS
	Anti-nucleosome	40	1.91 ± 0.204	62	1.88 ± 0.212	NS
	Anti-SSA/SSB	32	2.03 ± 0.258	70	2.01 ± 0.176	NS
	Anti-RNP	22	1.95 ± 0.253	80	1.96 ± 0.165	NS
Medical therapy
	Prednisone dose ≥30 mg/day	48	2.08 ± 0.175	54	1.94 ± 0.181	NS
	Immunosuppressants^b	42	2.00 ± 0.141	60	1.54 ± 0.151	0.0365

^adsDNA, Double-stranded DNA; NS, Not significant; RNP, Ribonucleoprotein; SEM, Standard error of the mean; SLE, Systemic lupus erythematosus; Sm, Smith; SSA, Sjögren’s syndrome–related antigen A; SSB, Sjögren’s syndrome–related antigen B. ^bImmunosuppressants included azathioprine, cyclophosphamide, cyclosporine A, FK506 (tacrolimus), leflunomide, mycophenolate mofetil and methotrexate.

ISSN: 1478-6362